A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects
Open Access
- 6 February 2023
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (3) , 155-165
Abstract
Background and Objective Perampanel is a once-daily oral anti-seizure medication indicated for focal-onset seizures and generalized tonic-clonic seizures. This study investigated the single- and multiple-dose pharmacokinetics of perampanel in healthy Chinese adults. Methods Study 052 (NCT03424564) was a phase I, single-center, open-label, parallel-group study. In the single-dose part of the study, subjects received a single oral dose of perampanel 2, 4, or 8 mg. In the multiple-dose part, subjects received once-daily oral perampanel 2 mg on Days 1–7 and 4 mg on Days 8–21. Pharmacokinetic parameters were determined from perampanel plasma concentrations using non-compartmental analysis. Dose proportionality after single doses of perampanel was assessed. Safety and tolerability were evaluated. Results In the single-dose part (N = 30), median time to reach maximum concentration (tmax) was 0.75–1.0 h, mean terminal elimination phase half-life (t½) was 85.6–122 h, mean maximum observed concentration (Cmax) was 77.9–276 ng/mL, and mean area under the concentration–time curve from time zero to time of the last quantifiable concentration (AUC(0-t)) was 4070–15100 ng·h/mL. Single-dose pharmacokinetics were linear for perampanel 2–8 mg. In the multiple-dose part (N = 12), Day 21 steady-state (4 mg/day) parameters were median time at which the highest drug concentration occurs at steady state (tss,max), 1.25 h; mean t½, 109 h; mean maximum observed concentration at steady state (Css,max), 453 ng/mL; and mean area under the concentration–time curve over the dosing interval on multiple dosing (AUC(0- τ)), 7540 ng·h/mL. For single- and multiple-dose perampanel, the most common treatment-emergent adverse events were dizziness and somnolence. Conclusions Single- and multiple-dose pharmacokinetics of perampanel in healthy Chinese adults revealed rapid perampanel absorption, slow elimination, and a linear relationship with single perampanel doses of 2–8 mg. Findings were consistent with previous studies of perampanel pharmacokinetics in other ethnic/racial populations of healthy subjects. Single and multiple doses of perampanel were generally safe and well tolerated. Clinical Trial Registration NCT03424564; registered February 2018.Keywords
Funding Information
- Eisai Co., Ltd.
This publication has 13 references indexed in Scilit:
- Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizuresActa Neurologica Scandinavica, 2017
- An inter‐laboratory cross‐validation study for the determination of perampanel in human plasma by liquid chromatography assaysBiomedical Chromatography, 2016
- Perampanel for tonic-clonic seizures in idiopathic generalized epilepsyNeurology, 2015
- High-performance liquid chromatography–tandem mass spectrometry method for the determination of perampanel, a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2015
- The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonistEpilepsia, 2014
- Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305Epilepsia, 2012
- Adjunctive perampanel for refractory partial-onset seizuresNeurology, 2012
- Randomized phase III study 306Neurology, 2012
- Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsyEpilepsia, 2011
- The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology StudiesClinical Pharmacology & Therapeutics, 2008